American Fork, Utah (Hexa PR Wire — November 7, 2026) —
Two drug teams are pulling the same lever in opposite directions, and both report that it works. One switches on the receptor for a gut hormone called GIP. The other blocks it. Each pairs the move with a second hormone, GLP-1, and each has produced clinical results. A 2025 review in the Journal of Clinical Medicine puts the problem plainly: whether to activate or block the GIP receptor to treat obesity is still an open question. That paradox is one of the most interesting unresolved arguments in metabolic research, and it shows how much a peptide’s story depends on context.
A hormone with a reputation problem
GIP was the first incretin hormone to be discovered. Incretins are signals the gut sends after a meal, and they amplify the insulin response. GIP is released by K cells in the intestine and GLP-1 by L cells. Both are short-lived in the blood. GIP has a half-life of about seven minutes before an enzyme called DPP-4 inactivates it. Research soon ran ahead on GLP-1 instead, and GIP picked up a bad name along the way.
That reputation rested on loss-of-function work. A 2021 review in Molecular Metabolism by Jonathan Campbell points out that the long-standing idea that GIP drives weight gain comes exclusively from experiments that removed GIP signaling. Nobody had shown that activating the receptor adds body fat or body weight. Human genetics added to the suspicion, because genome-wide association studies linked the GIPR gene to body mass index. On that logic, the sensible drug would block GIP, not mimic it.
The experiment that should have ended the agonist idea
The human evidence for activating GIP alone was thin. According to the Douros review, infusing native GIP into people with obesity did not reduce how much they ate, and pairing it with the GLP-1 drug liraglutide did not reduce intake any further. A hormone that lasts seven minutes and does nothing to appetite does not look like a drug candidate.
The Douros review is useful here because it separates the kinds of evidence. It looks at human physiology, human genetics, rodent genetic models, and pharmacology studies in rodents and non-human primates, then asks which early findings carried over into the clinic and which did not. The answer is mixed, and that mix is the reason the argument is still running.
The antagonist side looked better in animals. In mice fed a fattening diet, a GIP receptor antagonist on its own produced little weight loss. Combined with liraglutide, it nearly doubled the loss seen with liraglutide alone. Other groups, using a different blocking antibody and a blocking peptide, reported similar outcomes.
Two programs, one receptor, opposite moves
The agonist program produced tirzepatide, a single peptide that activates both the GIP receptor and the GLP-1 receptor. The antagonist program produced maridebart cafraglutide, known as MariTide, which links an antibody that blocks the GIP receptor to GLP-1 peptides. Both approaches have reached clinical testing. The Douros review describes them as programs that look contradictory on paper, then walks through the evidence that motivated each one.
Tirzepatide is also not an even split between its two targets. A 2020 paper in JCI Insight by Willard and colleagues calculated receptor occupancy at clinically used doses and found that the molecule engages the GIP receptor more than the GLP-1 receptor. At the GIP receptor it behaves like native GIP. At the GLP-1 receptor it is biased, favoring production of the signaling messenger cAMP over recruitment of a protein called β-arrestin, and it drives less receptor internalization than GLP-1 itself. In pancreatic islets, β-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide, which suggests the bias helps insulin secretion. In other words, the word “dual” overstates how even the split is.
The same paper reported that early trials in type 2 diabetes pointed to outcomes beyond those of a selective GLP-1 drug. A Cambridge group reviewing the receptor explores what might explain the better weight loss seen with tirzepatide, compared with GLP-1-only agonists.
Four attempts to square the circle
None of these explanations is settled, and each is best read as a hypothesis.
The first is desensitization. A review from Lafferty, Flatt, Gault and Irwin notes that prolonged GIP receptor agonism may numb the receptor until it behaves as if it were blocked, and that this effect may be stronger in humans than in rodents. If that is right, the two camps may be reaching the same place by different roads.
The second is tissue. The GIP receptor appears in select cell types around the body, and several of them influence body weight. Campbell’s review adds that mapping which ones matter has been hard, partly because good tools for detecting the receptor have been scarce.
The third is the brain. A recent review from the Cambridge group examines how the receptor shapes appetite and body weight, and describes a proposed mechanism in which receptor activation influences neural pathways indirectly, through glial cells called oligodendrocytes.
The fourth is context. The Douros review says human data and rodent genetics together suggest that GIP acts as an obesogenic factor in the setting of overnutrition. The same hormone may behave differently in a lean body than in one that is overfed.
What the paradox says about reading peptide studies
The lesson reaches well beyond GIP. Receptor biology is conditional. What a compound does depends on dose, duration, tissue, species and what else is on board. A study reporting that a molecule activates a receptor has told you one fact, and GIP shows how far a single fact can mislead. For years, mouse studies pointed one way, and clinical programs eventually went the other.
A few questions make any mechanism claim easier to weigh. Which species was studied, and does the finding hold in people? Which tissue was measured? Was the exposure brief or prolonged, given the desensitization question above? And was the compound given alone or alongside another hormone? The GIP literature shows that the answers can reverse the conclusion.
Approval status adds a second layer. Tirzepatide is an approved prescription drug, made under pharmaceutical manufacturing controls and tested in large human trials. Research-grade material sold by a supplier is a different product with a different record, and what the trials showed belongs to the approved drug.
Spanish-language suppliers tend to describe the compound in those terms. Tirzepatida Costa Rica states on its homepage that its products are intended exclusively for research and not for human consumption. Its Spanish-language about page, at tirzepatida.cr/sobre-nosotros, calls tirzepatide a synthetic peptide studied for its interaction with GIP and GLP-1 receptors. That is a fair summary of the science, and it also marks the line a reader should keep in view. Interest in a receptor mechanism is one thing. The evidence behind an approved medicine is another, and it does not transfer to a different product.
Where the question stands
GIP was written off, rehabilitated and then complicated again. One sentence recurs in reviews of this field, and it is a plain one: a deeper understanding of GIP biology is still needed before anyone can say exactly how modulating this system changes metabolism. That is where the research sits in November 2026, and any claim that sounds more settled deserves a look at its source.
